Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02917395
Recruitment Status : Unknown
Verified October 2016 by Idit Yedidya, Rabin Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : September 28, 2016
Last Update Posted : October 4, 2016
Sponsor:
Information provided by (Responsible Party):
Idit Yedidya, Rabin Medical Center

Brief Summary:

Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.

Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.


Condition or disease Intervention/treatment Phase
Cardiomyopathy Device: echocardiography Not Applicable

Detailed Description:
Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients; Comparison of Two Echocardiography Based Methods: Global Longitudinal Strain vs. Left Ventricle Ejection Fraction
Study Start Date : November 2016
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : June 2018


Arm Intervention/treatment
Experimental: echo

Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.

Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Device: echocardiography
Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.




Primary Outcome Measures :
  1. Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide [ Time Frame: 2-3 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hypertrophic cardiomyopathy that treated with disopyramid

Exclusion Criteria:

  • pregnancy
  • pacemaker

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02917395


Contacts
Layout table for location contacts
Contact: Idit Yedidya, md 972-3-9372242 iditye@clalit.org.il

Sponsors and Collaborators
Rabin Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Idit Yedidya, MD Rabin Medical Center

Layout table for additonal information
Responsible Party: Idit Yedidya, Head of echo lab- hashron campus in Rabin medical center, Rabin Medical Center
ClinicalTrials.gov Identifier: NCT02917395     History of Changes
Other Study ID Numbers: 0538-16-RMC
First Posted: September 28, 2016    Key Record Dates
Last Update Posted: October 4, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Idit Yedidya, Rabin Medical Center:
hypertrophic cardiomyopathy, disopyramide,
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophy
Heart Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Heart Valve Diseases
Disopyramide
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action